European Inter-Institutional Impact Study of MammaPrint
PUBLICATION: The Breast August 2014, Volume 23, Issue 4, Pages Read More
Agendia Co-Founder and CSO Develops Method to Identify Women Who Will Benefit from Tamoxifen Therapy for Breast Cancer
IRVINE, CA and AMSTERDAM, July 31, 2014 – Innovative research Read More
Agendia and CBLPath Announce Agreement to Assist Physicians in Diagnostic Assessment of Breast Cancer
IRVINE, CA, AMSTERDAM and Rye Brook, N.Y., July 16, 2014 Read More
Value of Breast Cancer Molecular Subtyping Documented by Independent Study Comparing Genomic Tests at ASCO 2014 Meeting
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, June 10, 2014 – Read More
African-American Women More Likely to Be Diagnosed with Higher Risk Breast Cancer
Washington, D.C., June 9, 2014 – A research study led Read More
Optimized Outcome Prediction in Breast Cancer by Combining the 70-Gene Signature with Clinical Risk Prediction Algorithms
PUBLICATION: Breast Cancer Res Treat. 2014 Jun;145(3):697-705. doi: 10.1007/s10549-014-2954-2. Epub Read More
Multiple Studies on Agendia’s MammaPrint and BluePrint Tests to Be Featured at ASCO Annual Meeting
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, May 22, 2014– New Read More
Molecular Subtyping with Agendia Tests Can Provide Better Guidance for Breast Cancer Treatment, New Research Reports
Presentations to American Society of Breast Surgeons Detail Clinical Insights Read More
Agendia Announces New Agreement with Daiichi Sankyo to Support Oncology Drug Development
Companies Will Apply Agendia Oncology Biomarker Expertise to Daiichi Sankyo Read More
Risk Estimations and Treatment Decisions in Early Stage Breast Cancer: Agreement Among Oncologists and the Impact of the 70-Gene Signature
PUBLICATION: Eur J Cancer. 2014 Apr;50(6):1045-54. doi: 10.1016/j.ejca.2014.01.016. Epub 2014 Read More
